DI NA KELANGAN NG BAKUNA NA DI EFFECTIVE
The trial's results suggest that Pfizer's drug surpasses Merck & Co Inc's (MRK.N) pill, molnupiravir, which was shown last month to halve the chance of dying or being hospitalized for COVID-19 patients at high risk of serious illness.
Pfizer's pill, with the brand name Paxlovid, could secure U.S. regulatory approval by the end of the year. Pfizer said it plans to submit interim trial results to the Food and Drug Administration (FDA) before the Nov. 25 U.S. Thanksgiving holiday. The trial was stopped early due to its high success rate.
You do not have permission to view the full content of this post. Log in or register now.
Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%
Nov 5 (Reuters) - Pfizer Inc's (PFE.N) experimental antiviral pill to treat COVID-19 cut by 89% the chance of hospitalization or death for adults at risk of severe disease, the company said on Friday, as its CEO vowed to make this promising new weapon in the fight against the pandemic available globally as quickly as possible.The trial's results suggest that Pfizer's drug surpasses Merck & Co Inc's (MRK.N) pill, molnupiravir, which was shown last month to halve the chance of dying or being hospitalized for COVID-19 patients at high risk of serious illness.
Pfizer's pill, with the brand name Paxlovid, could secure U.S. regulatory approval by the end of the year. Pfizer said it plans to submit interim trial results to the Food and Drug Administration (FDA) before the Nov. 25 U.S. Thanksgiving holiday. The trial was stopped early due to its high success rate.
You do not have permission to view the full content of this post. Log in or register now.